Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Single Arm NCRI Feasibility Study of CHOP in Combination With Ofatumumab in Induction and Maintenance for Patients With Newly Diagnosed Richter's Syndrome.

Next Previous
Trial Profile

Single Arm NCRI Feasibility Study of CHOP in Combination With Ofatumumab in Induction and Maintenance for Patients With Newly Diagnosed Richter's Syndrome.

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 01 Nov 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ofatumumab (Primary) ; Cyclophosphamide; Doxorubicin; Prednisone; Vincristine
  • Indications Chronic lymphocytic leukaemia; Diffuse large B cell lymphoma; Richter's syndrome
  • Focus Therapeutic Use
  • Acronyms CHOP-OR

Most Recent Events

  • 27 May 2015 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.
  • 27 May 2015 Planned End Date changed from 1 Feb 2016 to 1 Apr 2016 as reported by ClinicalTrials.gov record.
  • 07 Jan 2015 Accrual to date is 107% according to United Kingdom Clinical Research Network record.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top